Abstract:Highlights • Methyltransferase like 14 (METTL14) significantly inhibits the growth of tumor in vitro. • The combination of METTL14 and TLR4 agonist could induce M1 polarization of macrophages. • We constructed the cyclic (Arg-Gly-Asp) (cRGD) peptide modified macrophage membrane-coated nanovesicles to co-deliver METTL14 and TLR4 agonist. • This nanovesicles could dual-target tumor and macrophages to inhibit tumor and induce M1 polarization of macrophages. Background Immunosuppressive M2 macrophages in the tumor microenvironment (TME) can mediate the therapeutic resistance of tumors, and seriously affect the clinical efficacy and prognosis of tumor patients. This study aims to develop a novel drug delivery system for dual-targeting tumor and macrophages to inhibit tumor and induce macrophage polarization. Methods The anti-tumor effects of methyltransferase like 14 (METTL14) were investigated both in vitro and in vivo. The underlying mechanisms of METTL14 regulating macrophages were also explored in this study. We further constructed the cyclic (Arg-Gly-Asp) (cRGD) peptide modified macrophage membrane-coated nanovesicles to co-deliver METTL14 and the TLR4 agonist. Results We found that METTL14 significantly inhibits the growth of tumor in vitro. METTL14 might downregulate TICAM2 and inhibit the Toll-like receptor 4 (TLR4) pathway of macrophages, meanwhile, the combination of METTL14 and the TLR4 agonist could induce M1 polarization of macrophages. Macrophage membrane-coated nanovesicles are characterized by easy modification, drug loading, and dual-targeting tumor and macrophages, and cRGD modification can further enhance its targeting ability. It showed that the nanovesicles could improve the in vivo stability of METTL14, and dual-target tumor and macrophages to inhibit tumor and induce M1 polarization of macrophages. Conclusions This study anticipates achieving the dual purposes of tumor inhibition and macrophage polarization, and providing a new therapeutic strategy for tumors. Graphical abstract Download : Download high-res image (309KB) Download : Download full-size image

MMP2 enzyme-responsive extracellular vesicles as dual-targeted carriers to promote the phagocytosis of macrophages

Roles of M1 Macrophages and Their Extracellular Vesicles in Cancer Therapy

Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery via SNARE-mediated membrane fusion.

Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery <i>via</i> SNARE-mediated membrane fusion

Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization

Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy

Small Extracellular Vesicles-Mediated Cellular Interactions Between Tumor Cells and Tumor-Associated Macrophages: Implication for Immunotherapy.

Tumor-derived extracellular vesicles regulate macrophage polarization: role and therapeutic perspectives

Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation

Engineered Bacterial Outer Membrane Vesicles as Controllable Two‐way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy

Building Stable Mmp2-Responsive Multifunctional Polymeric Micelles by an All-In-One Polymer-Lipid Conjugate for Tumor-Targeted Intracellular Drug Delivery

M2 Macrophage Derived Extracellular Vesicle-Mediated Transfer of MiR-186-5p Promotes Colon Cancer Progression by Targeting DLC1

Phospholipid-Anchored Ligand Conjugation on Extracellular Vesicles for Enhanced Cancer Targeting

Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy

Engineered Extracellular Vesicles Expressing Siglec‐10 Camouflaged AIE Photosensitizer to Reprogram Macrophages to Active M1 Phenotype and Present Tumor‐Associated Antigens for Photodynamic Immunotherapy

Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting

Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer

Engineering small extracellular vesicles with multivalent DNA probes for precise tumor targeting and enhanced synergistic therapy

M2 macrophage microvesicle-inspired nanovehicles improve accessibility to cancer cells and cancer stem cells in tumors

Engineering extracellular vesicles derived from macrophages for tumor therapy: a review